The Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium has been awarded a $30.8M grant over five years to research the most effective treatment options for future clinical testing.
A large trial of a new drug regimen for tuberculosis, designed in part by School researchers, leads to a new WHO recommendation for treating the disease.